Virginia Ferraresi

Research interests

Publications

• Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

  Journal of Clinical Oncology · 2022 · 10.1200/jco.21.02961

• Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.005

• Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.07.006

• Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.08.1995

• Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

  ESMO Open · 2021 · https://doi.org/10.1016/j.esmoop.2021.100170

• Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.03289

• Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

  European Journal of Cancer · 2019 · 10.1016/j.ejca.2019.07.001

• Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

  Annals of Oncology · 2018 · 10.1093/annonc/mdy320

• Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy095

• Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy321

• Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy310

• Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy096

• EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma

  Tumori Journal · 2017 · 10.5301/tj.5000696

• Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

  Annals of Oncology · 2017 · 10.1093/annonc/mdx176

• Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30334-0

• Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30231-0

• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1611299

• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet · 2015 · 10.1016/s0140-6736(15)60898-4

• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70122-1

• Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)71136-2

• Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1406037

• Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

  Cancer Immunology Immunotherapy · 2014 · 10.1007/s00262-014-1545-8

• Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

  European Journal of Cancer · 2013 · 10.1016/j.ejca.2013.09.007

• Phase II Study of Imatinib in Advanced Chordoma

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.35.3656

• Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients

  BMC Cancer · 2010 · 10.1186/1471-2407-10-22

Current projects

No projects listed.